Rosetta Genomics this week announced that it has established a US sales team that will handle the commercialization of its suite of microRNA-based diagnostics.
The team will particularly focus on Rosetta's miRview Mets and miRview Mets 2 tests, which are designed to determine the source of cancers of unknown primary origin.
Rosetta did not specify the size of the team, but said it will expand it “over the coming quarters.”
The move has long been expected after a dispute between Rosetta and its one-time US distribution partner Prometheus Laboratories resulted in the miRNA company regaining the market rights to its products (GSN 12/2/2010). Rosetta continues to sell its products through distributors outside of the US.